Category: Vestibular Training

Dizziness Drug May Improve Long-term Memory, Say University of Tokyo Researchers

During recent studies by researchers in Japan, histamine improved people’s long-term memory test scores depending on the strength of the original memory and could temporarily extend mice memories by as much as 25 days longer than normal. Clarifying the role of histamine in memory may help alleviate symptoms of memory disorders, such as Alzheimer’s disease and other forms of dementia.

Read More

NIDCD’s Mission Focuses on Hearing and Balance Research

According to Judith Cooper, PhD—acting director of the NIDCD and director of the NIDCD Division of Scientific Programs who is quoted in the article—NIDCD research is primarily focused on identifying hearing loss genes; determining barriers to treatment and evaluating new “service delivery and screening models,” and the application of cochlear implant technology in the development of “other neural prostheses.”

Read More

Sensorion and Pasteur Institute to Collaborate on Gene Therapy Products

Sensorion announced a letter of intent with Pasteur Institute in Paris to exclusively negotiate a framework agreement to obtain the exclusive licenses to develop and commercialize gene therapy product candidates for restoration, treatment, and prevention of hearing loss disorders. They will collaborate on several lead programs to correct monogenic forms of hereditary hearing loss including, among others, the Usher syndrome type 1 and otoferlin deficiency, according to the announcement.

Read More

DizzyDoctor to Partner with Seamgen on Vertigo Recording Application

The data, if collected properly, will help allow a physician to better identify why a patient has episodes of dizziness. Recordings from the application—including video, motion, and pupil tracking—are all said to be automatically uploaded to the DizzyDoctor website. For a fee, this data can be processed for the purpose of diagnosing.

Read More

Sensorion Announces Publication of Seliforant Phase 1 Study Data

Seliforant (formerly SENS-111) is currently being studied in an ongoing Phase 2 trial for the treatment of acute unilateral vestibulopathy, a debilitating disease of the inner ear. Its maker, Sensorion, has announced the publication of data in the ‘British Journal of Clinical Pharmacology’ from a Phase 1 study evaluating the safety, tolerability, pharmacokinetics of the drug in healthy subjects. More data are expected at the end of 2018.

Read More